Optimal P2Y12-receptor treatmeNt Guided by bedSIDe Genetic or Pharmacodynamic TESTing to Prevent Periprocedural Myonecrosis During Elective Percutaneous Coronary Intervention.

Trial Profile

Optimal P2Y12-receptor treatmeNt Guided by bedSIDe Genetic or Pharmacodynamic TESTing to Prevent Periprocedural Myonecrosis During Elective Percutaneous Coronary Intervention.

Recruiting
Phase of Trial: Phase III

Latest Information Update: 25 Jan 2018

At a glance

  • Drugs Clopidogrel (Primary) ; Prasugrel (Primary)
  • Indications Embolism and thrombosis; Ischaemia; Muscle necrosis
  • Focus Pharmacogenomic; Therapeutic Use
  • Acronyms ONSIDE TEST
  • Most Recent Events

    • 20 Jan 2018 Planned End Date changed from 1 May 2014 to 1 May 2018.
    • 20 Jan 2018 Planned primary completion date changed from 1 Mar 2014 to 1 Mar 2018.
    • 30 Aug 2017 Results of subanalysis (n=94) assessing impact of prasugrel on the incidence of periprocedural myocardial injury among stable coronary artery disease patients, presented at the ESC Congress 2017: Annual Congress of the European Society of Cardiology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top